Literature DB >> 16091229

Management of antiretroviral therapy in neonates, children, and adolescents.

Michael Neely1, Andrea Kovacs.   

Abstract

There have been tremendous advances in the prevention of maternal-to-child transmission of HIV and treatment of HIV-infected children and adolescents. Although multiple classes of anti-HIV drugs are available that can control viral replication and stabilize immune function when used in combination, patients and their providers must also manage complex and frequently toxic regimens. This article updates our original report that summarizes official National Institutes of Health guidelines for the prevention of perinatal HIV infection and the management of pediatric and adolescent HIV infection and provides the most current updates on indications for therapy, recommended first-line therapy, criteria for changing therapy, salvage therapy, novel management strategies, and a comprehensive summary of available antiretroviral agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091229     DOI: 10.1007/s11904-004-0014-y

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  43 in total

1.  Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution.

Authors:  Homayoun Khanlou; Vijayabhaskar R Kandula; Vivian Yeh; Tomiko G Stein; Susan Sanchez; Juan-Carlos Ricaurte; Laveeza Bhatti; Charles F Farthing; Juan-Carlos Ricuarte
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

2.  Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group.

Authors:  A Kovacs; M Schluchter; K Easley; G Demmler; W Shearer; P La Russa; J Pitt; E Cooper; J Goldfarb; D Hodes; M Kattan; K McIntosh
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

3.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

4.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

5.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.

Authors:  D Jaquet; M Lévine; E Ortega-Rodriguez; A Faye; M Polak; E Vilmer; C Lévy-Marchal
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

Review 7.  Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects.

Authors:  Franco Lori; Andrea Foli; Julianna Lisziewicz
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

8.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

9.  Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.

Authors:  Rohan Hazra; Frank M Balis; Antonella N Tullio; Ellen DeCarlo; Carol J Worrell; Seth M Steinberg; John F Flaherty; Kitty Yale; Marianne Poblenz; Brian P Kearney; Lijie Zhong; Dion F Coakley; Stephane Blanche; Jean Louis Bresson; Judith A Zuckerman; Steven L Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Tenofovir disoproxil fumarate.

Authors:  Joel E Gallant; Stanley Deresinski
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

View more
  2 in total

1.  Characteristics of HIV-infected children recently diagnosed in Paris, France.

Authors:  Eugenia Macassa; Marianne Burgard; Florence Veber; Capucine Picard; Bénédicte Neven; Nizar Malhaoui; Christine Rouzioux; Stéphane Blanche
Journal:  Eur J Pediatr       Date:  2006-06-24       Impact factor: 3.183

2.  Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.

Authors:  Beatriz Larru; Jessica Eby; Elizabeth D Lowenthal
Journal:  Pediatric Health Med Ther       Date:  2014-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.